Known to confer increased kinase activity [48], this mutation may sensitise the patient to BRAF +/− MEK inhibitor therapy. Of interest in CRPC [30], with a report of response to targeted therapy in a BRAF mutant patient [52], clinical trials of MEK inhibitors are currently underway (...